TORRENT PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of TORRENT PHARMACEUTICALS have increased by 11.51% YoY .
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 15.39 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
TORRENT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 500420|NSE : TORNTPHARM]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹10,728 Cr | ₹9,620 Cr | ₹8,508 Cr | ₹8,005 Cr | ₹7,939 Cr |
| Expenses | ₹7,364 Cr | ₹6,796 Cr | ₹6,077 Cr | ₹5,524 Cr | ₹5,769 Cr |
| Operating Profit (Excl OI) | ₹3,364 Cr | ₹2,824 Cr | ₹2,431 Cr | ₹2,480 Cr | ₹2,170 Cr |
| Other Income | ₹62 Cr | ₹63 Cr | ₹197 Cr | ₹57 Cr | ₹121 Cr |
| Interest | ₹354 Cr | ₹333 Cr | ₹255 Cr | ₹353 Cr | ₹451 Cr |
| Depreciation | ₹808 Cr | ₹707 Cr | ₹662 Cr | ₹658 Cr | ₹654 Cr |
| Profit Before Tax | ₹2,352 Cr | ₹1,847 Cr | ₹1,226 Cr | ₹1,526 Cr | ₹1,187 Cr |
| Profit After Tax | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr |
| Consolidated Net Profit | ₹1,656 Cr | ₹1,245 Cr | ₹777 Cr | ₹1,252 Cr | ₹1,025 Cr |
| Earnings Per Share (Rs) | ₹56.47 | ₹48.94 | ₹36.79 | ₹45.92 | ₹73.97 |
| PAT Margin (%) | 11.34 | 9.92 | 7.63 | 5.11 | 8.41 |
| ROE(%) | 26.46 | 25.38 | 20.50 | 13.18 | 23.49 |
| ROCE(%) | 27.32 | 24.28 | 20.32 | 14.35 | 17.62 |
| Total Debt/Equity(x) | 0.40 | 0.57 | 0.85 | 0.68 | 0.83 |
Key Financials |
||
| Market Cap | : | ₹ 126,424.5 Cr |
| Revenue (TTM) | : | ₹ 12,248.0 Cr |
| Net Profit(TTM) | : | ₹ 2,140.0 Cr |
| EPS (TTM) | : | ₹ 63.2 |
| P/E (TTM) | : | 59.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| TORRENT PHARMACEUTICALS | -0.3% | 3.8% | 15.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 2% | 6.1% | 4.7% |
| DIVIS LABORATORIES | 0.1% | -3.5% | 8% |
| CIPLA | 1.1% | -1.1% | 2.6% |
| DR REDDYS LABORATORIES | 2% | 4.8% | 4.8% |
| MANKIND PHARMA | -0.6% | -8.8% | -11.9% |
| ZYDUS LIFESCIENCES | 1% | -5.1% | -0.9% |
| LUPIN | 2.1% | 7.3% | 3.7% |
| AUROBINDO PHARMA | 0.6% | 10.2% | NA |
TORRENT PHARMACEUTICALS Revenues
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 11.51 % |
| 5 Yr CAGR | 7.82 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹10,728 Cr | 11.51 | |
| Mar2024 | ₹9,620 Cr | 13.07 | |
| Mar2023 | ₹8,508 Cr | 6.29 | |
| Mar2022 | ₹8,005 Cr | 0.82 | |
| Mar2021 | ₹7,939 Cr | - | |
TORRENT PHARMACEUTICALS Operating Profit
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 19.11 % |
| 5 Yr CAGR | 11.58 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹3,364 Cr | 19.11 | |
| Mar2024 | ₹2,824 Cr | 16.15 | |
| Mar2023 | ₹2,431 Cr | -1.97 | |
| Mar2022 | ₹2,480 Cr | 14.27 | |
| Mar2021 | ₹2,170 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 6.81 % |
| 5 Yr CAGR | 3.48 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 31.35% | 6.81 | |
| Mar2024 | 29.35% | 2.69 | |
| Mar2023 | 28.58% | -7.75 | |
| Mar2022 | 30.98% | 13.31 | |
| Mar2021 | 27.34% | - | |
TORRENT PHARMACEUTICALS Profit After Tax
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 33.02 % |
| 5 Yr CAGR | 12.76 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,656 Cr | 33.02 | |
| Mar2024 | ₹1,245 Cr | 60.22 | |
| Mar2023 | ₹777 Cr | -37.92 | |
| Mar2022 | ₹1,252 Cr | 22.17 | |
| Mar2021 | ₹1,025 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 14.31 % |
| 5 Yr CAGR | 7.76 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 11.34 % | 14.31 | |
| Mar2024 | 9.92 % | 30.01 | |
| Mar2023 | 7.63 % | 49.32 | |
| Mar2022 | 5.11 % | -39.24 | |
| Mar2021 | 8.41 % | - | |
TORRENT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 15.39 % |
| 5 Yr CAGR | -6.53 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹56 | 15.39 | |
| Mar2024 | ₹49 | 33.03 | |
| Mar2023 | ₹37 | -19.88 | |
| Mar2022 | ₹46 | -37.92 | |
| Mar2021 | ₹74 | - | |
TORRENT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 500420|NSE : TORNTPHARM]
| Y-o-Y | 12.52 % |
| 5 Yr CAGR | 11.59 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 27.32% | 12.52 | |
| Mar2024 | 24.28% | 19.49 | |
| Mar2023 | 20.32% | 41.60 | |
| Mar2022 | 14.35% | -18.56 | |
| Mar2021 | 17.62% | - | |
TORRENT PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹3,736.0 |
| Current MarketCap | : | ₹ 126,424.5 Cr |
| Updated EOD on | : | Dec 01,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TORRENT PHARMACEUTICALS | -0.3% |
3.8% |
15.5% |
| SENSEX | 0.9% |
0.8% |
7.1% |
TORRENT PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE MOMENTUM INDEX | 1.3% | -0.8% | 2.8% |
| BSE 200 EQUAL WEIGHT | 1.1% | -0.5% | 5.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY NEXT 50 | 1.8% | -1.5% | -0.4% |
| NIFTY PHARMA | 1.8% | 2% | 4.2% |
| NIFTY INDIA MANUFACTURING | 1.7% | -0% | 9.7% |
| NIFTY100 EQUAL WEIGHT | 1.2% | -0.9% | 7.2% |
| NIFTY LARGEMIDCAP 250 | 1.2% | 0.5% | 7.6% |
You may also like the below Video Courses
FAQ about TORRENT PHARMACEUTICALS Financials
How the annual revenues of TORRENT PHARMACEUTICALS have changed ?
The Revenues of TORRENT PHARMACEUTICALS have increased by 11.51% YoY .
How the Earnings per Share (EPS) of TORRENT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of TORRENT PHARMACEUTICALS has increased by 15.39 % YoY .
Check out Intrinsic Value of Peers of TORRENT PHARMACEUTICALS
Compare Stock Analytics of Peers of TORRENT PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
